Related Experiment Videos
Hemofiltration in diabetic uremic patients
Insights
Hemofiltration (HF) offers promising results for Diabetic Uremic Patients (DUP) undergoing substitutive treatment (ST). This study shows HF improves vascular stability and hypertension control, presenting a viable alternative to C.A.P.D.
Area of Science:
- Nephrology
- Diabetology
- Internal Medicine
Background:
- Diabetic Uremic Patients (DUP) present unique challenges for substitutive treatment (ST).
- Continuous Ambulatory Peritoneal Dialysis (C.A.P.D.) is well-documented, but Hemofiltration (HF) is less explored for DUP.
- Existing ST options for DUP often yield disappointing clinical results and side effects.
Purpose of the Study:
- To evaluate the potential of Hemofiltration (HF) as a substitutive treatment (ST) for Diabetic Uremic Patients (DUP).
- To assess the clinical outcomes and feasibility of postdilutional HF in a cohort of DUP.
Main Methods:
- Retrospective analysis of data from 6 DUP treated with postdilutional HF.
- Multi-center data collection over a 10.6 months/patient period.
- Evaluation of key clinical parameters including vascular stability, blood pressure, retinopathy, complications, and hospitalization.
Main Results:
- HF treatment demonstrated good vascular stability in DUP.
- Effective control of arterial hypertension and retinopathy was observed.
- Reduced clinical complications and hospitalization rates were noted with HF therapy.
- HF showed potential in managing DUP when C.A.P.D. is unmanageable.
Conclusions:
- Hemofiltration (HF) is a viable and effective substitutive treatment (ST) option for Diabetic Uremic Patients (DUP).
- HF offers significant benefits in managing hypertension, retinopathy, and overall clinical stability.
- HF can serve as a valuable alternative or adjunct to C.A.P.D. for DUP, ensuring continuous treatment.
Abstract:
The increasing number of Diabetic Uremic Patients (DUP) starting the substitutive treatment (ST) constitutes a difficult and often disappointing problem in terms of efforts, clinical results and side-effects. While treatment of these patients by C.A.P.D. is well documented, the adoption of Hemofiltration (HF), has been, up to now scarcely considered. In order to define the potentialities of a HF policy in the treatment of these patients, data from 6 DUP treated with postdilutional HF for a 10.6 months/patient period were collected on a multi-center basis and retrospectively examined. Good results were achieved in terms of vascular stability, control of arterial hypertension and of retinopathy, clinical complications and hospitalization rate. Although C.A.P.D. may represent a first choice treatment for DUP with residual function, satisfactory glicemic control, difficult blood access and a motivation to full autonomization, HF may constitute a logical alternative when C.A.P.D. should be unmanageable (visus impairment, history of repeated peritonitis and dismetabolism, considerable weight gain): an integration of HF and C.A.P.D. can assure PDU with a continuative treatment.